2. Signaling Pathways
  3. Apoptosis
    Metabolic Enzyme/Protease
  4. Glutathione Peroxidase
  5. Glutathione Peroxidase Inhibitor

Glutathione Peroxidase Inhibitor

Glutathione Peroxidase Inhibitors (77):

Cat. No. Product Name Effect Purity
  • HY-100218A
    RSL3
    		Inhibitor 99.87%
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
  • HY-100003
    ML-210
    		Inhibitor 99.93%
    ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity.
  • HY-100002
    ML162
    		Inhibitor 99.46%
    ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines
  • HY-P2818
    Alkaline phosphatase, Bovine intestine
    		Inhibitor
    Alkaline phosphatase, Bovine intestine (Apase) is an orally active membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline phosphatase, Bovine intestine reduces myeloperoxidase activity and bacterial translocation. Alkaline phosphatase, Bovine intestine improves survival rate of mice infected with E. coli. Alkaline phosphatase, Bovine intestine improves TNBS-induced colon inflammation.
  • HY-W996116
    AZM198
    		Inhibitor
    AZM198 is a selective, orally active, and irreversible MPO inhibitor with an IC50 of 15.0 nM. AZM198 has an IC50 of 19 μM for CYP3A4. AZM198 has favorable lipophilicity, membrane permeability, metabolic stability, safety, and pharmacokinetic properties. AZM198 exhibits activity in improving vascular function, atherosclerotic plaques, pulmonary hypertension, kidney disease, visceral inflammatory fat deposition, ectopic fat deposition, and hepatic fibrosis.
  • HY-Y0669
    Pipecolic acid
    		Inhibitor 99.92%
    Pipecolic acid is a metabolite of lysine and an immunomodulator, which can induce systemic acquired resistance (SAR) in plants. Pipecolic acid inhibits ferroptosis in diabetic retinopathy through the YAP-GPX4 signaling pathway. Pipecolic acid can induce apoptosis in neuronal cells. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxin-dependent epilepsy.
  • HY-138153
    JKE-1674
    		Inhibitor 99.54%
    JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors.
  • HY-141809
    GPX4-IN-3
    		Inhibitor 99.83%
    GPX4-IN-3 (26a) is a potent glutathione peroxidase 4 (GPX4) inhibitor as a selective ferroptosis inducer. GPX4-IN-3 (26a) exhibits 71.7% inhibition for GPX4 with 1 μM.
  • HY-B0182
    Carmofur
    		Inhibitor 99.95%
    Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).
  • HY-145581
    Mitiperstat
    		Inhibitor 99.12%
    Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease.
  • HY-N0070
    Solasonine
    		Inhibitor 99.19%
    Solasonine is a ferroptosis inducer which can be isolated from Solanum melongena that has anti-infection, anti-cancer, and neurogenesis promoting properties. Solasonine promotes ferroptosis of HCC cells via destruction of the glutathione redox system induced by inhibiting GPX4, and can be used for cancer research.
  • HY-17646
    Verdiperstat
    		Inhibitor 99.85%
    Verdiperstat (AZD3241) is a selective, irreversible and orally active myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and can be used in the research of neurodegenerative brain disorders.
  • HY-111341
    AZD5904
    		Inhibitor 99.93%
    AZD5904 is a selective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC50 of 140 nM and has similar potency in mouse and rat.
  • HY-114360
    Taurohyodeoxycholic acid
    		Inhibitor 99.73%
    Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula.
  • HY-100873
    PF-1355
    		Inhibitor 99.80%
    PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.
  • HY-B0679
    Lubiprostone
    		Inhibitor 99.09%
    Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research.
  • HY-155663
    GPX4-IN-5
    		Inhibitor 99.90%
    GPX4-IN-5 is a covalent inhibitor of GPX4 (IC50: 0.12 μM). GPX4-IN-5 can induce ferroptosis and has anti-tumor effects. GPX4-IN-5 can be used in the study of triple-negative breast cancer (TNBC).
  • HY-106228
    HLF1-11
    		Inhibitor 99.91%
    HLF1-11, a human lactoferrin-derived peptide, is a broad spectrum antimicrobial agent. HLF1-11 inhibits human MPO activity. HLF1-11 also directs GM-CSF-driven monocyte differentiation toward macrophages, and enhances immune responses.
  • HY-B0880
    4-Aminobenzohydrazide
    		Inhibitor 99.96%
    4-Aminobenzohydrazide (p-Aminobenzohydrazide) is an irreversible myeloperoxidase (MPO) inhibitor (IC50=0.3 μM) that induces oxidative stress burst in neutrophils (ROS IC50=43.6 μM). 4-Aminobenzohydrazide has been used in subacute stroke research.
  • HY-Y0669S
    Pipecolic acid-d9
    		Inhibitor 99.9%
    Pipecolic acid-d9 is the deuterium labeled Pipecolic acid. Pipecolic acid is a metabolite of lysine and an important precursor for many useful microbial secondary metabolites. Pipecolic acid slows ferroptosis in diabetic retinopathy by inhibiting the YAP-GPX4 signaling pathway. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxine-dependent epilepsy.